Precision Biosciences (DTIL) Liabilities from Discontinued Operations (2022 - 2025)
Precision Biosciences (DTIL) reported Liabilities from Discontinued Operations of 885000.0 for Q3 2025, down 32.13% year-over-year from 1304000.0 in Q3 2024, and little changed on a QoQ basis from 885000.0 in Q2 2025.
Precision Biosciences (DTIL) has 4 years of Liabilities from Discontinued Operations data on file, last reported at 885000.0 in Q3 2025.
- Quarterly Liabilities from Discontinued Operations fell 32.13% year-over-year to 885000.0 in Q3 2025, while the trailing twelve-month figure through Sep 2025 was 885000.0 (down 32.13% YoY) and the FY2024 annual result came in at 1204000.0, down 52.09% from the prior year.
- Liabilities from Discontinued Operations steadied at 885000.0 in Q3 2025 per DTIL's latest filing, from 885000.0 in the prior quarter.
- Across five years, Liabilities from Discontinued Operations topped out at 3465000.0 in Q4 2022 and bottomed at 885000.0 in Q1 2025.
- The 4-year median for Liabilities from Discontinued Operations is 1304000.0 (2024), against an average of 1559200.0.
- Peak annual rise in Liabilities from Discontinued Operations reached 20.54% in 2024, while the deepest fall reached 52.09% in 2024.
- Tracing DTIL's Liabilities from Discontinued Operations over 4 years: stood at 3465000.0 in 2022, then fell by 27.47% to 2513000.0 in 2023, then tumbled by 52.09% to 1204000.0 in 2024, then retreated by 26.5% to 885000.0 in 2025.
- Per Business Quant, the three latest DTIL Liabilities from Discontinued Operations figures stand at 885000.0 (Q3 2025), 885000.0 (Q2 2025), and 885000.0 (Q1 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,216,509.61 Bn | 1,216,509.61 Bn | - |
| 2 | Alterity Therapeutics | 764,224.41 Bn | 764,224.38 Bn | - |
| 3 | Legend Biotech | 2,716.00 Bn | 2,715.71 Bn | 242.10 Mn |
| 4 | Nanobiotix | 2,248.83 Bn | 2,248.77 Bn | - |
| 5 | Akari Therapeutics | 1,951.18 Bn | 1,951.17 Bn | - |
| 6 | Vertex Pharmaceuticals | 113.69 Bn | 106.44 Bn | 2.59 Bn |
| 7 | Evaxion A | 64.16 Bn | 64.14 Bn | - |
| 8 | Regeneron Pharmaceuticals | 63.94 Bn | 55.18 Bn | 3.31 Bn |
| 9 | Alnylam Pharmaceuticals | 40.13 Bn | 37.12 Bn | 959.66 Mn |
| 10 | Precision Biosciences | 171.70 Mn | 70.52 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2025 | 885,000.00 |
| Sep 30, 2025 | 885,000.00 |
| Jun 30, 2025 | 885,000.00 |
| Jun 30, 2025 | 885,000.00 |
| Mar 31, 2025 | 885,000.00 |
| Mar 31, 2025 | 885,000.00 |
| Dec 31, 2024 | 1.20 Mn |
| Dec 31, 2024 | 1.20 Mn |
| Sep 30, 2024 | 1.30 Mn |
| Sep 30, 2024 | 1.30 Mn |
| Jun 30, 2024 | 1.30 Mn |
| Jun 30, 2024 | 1.30 Mn |
| Mar 31, 2024 | 1.51 Mn |
| Mar 31, 2024 | 1.51 Mn |
| Dec 31, 2023 | 2.51 Mn |
| Dec 31, 2023 | 2.51 Mn |
| Sep 30, 2023 | 1.64 Mn |
| Sep 30, 2023 | 1.64 Mn |
| Dec 31, 2022 | 3.47 Mn |
| Dec 31, 2022 | 3.47 Mn |